Thelansis

  Patients with Non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation are a particular group of individuals. The etiology of cancer, the clinicopathological features, prognosis, and treatment paradigms are different from other NSCLC patients. EGFR mutations occur in 40%–60% of South-East Asian patients or 10%–20% of Caucasian patients with lung adenocarcinomas. Most EGFR mutation-positive tumors are in patients who were never smokers or light smokers, but the observation is not exclusive. Due to an increasing prevalence of non-smoking behavior, more female patients have EGFR mutations than male patients. In the Iressa Pan Asian Survival Study (IPASS) trial that accrued Asian non- or never smoking lung adenocarcinoma patients, 80% of the subjects were female. In this trial, 60% of the tumors harbored EGFR mutations.   The competitive landscape of EGFR – Non-small cell lung cancer includes country-specific approved and pipeline therapies...